Navigation Links
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy

Data Also Show Nebivolol Lowers Blood Pressure in Obese and Non-Obese Hypertensive Patients

CHICAGO, May 21, 2007 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. today presented positive data from two clinical studies and one pooled analysis of nebivolol, a selective beta 1-blocker with vasodilating properties currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension. Data from the two clinical studies show that nebivolol demonstrates blood pressure lowering effects as long-term therapy either alone or in combination with other agents, and also as part of a combination treatment for hypertension. The pooled analysis of three registration monotherapy trials supports nebivolol's blood pressure lowering effects for the treatment of hypertension in obese individuals, a difficult- to-treat patient population. The data were presented at the American Society of Hypertension, Inc. (ASH) 22nd Annual Scientific Meeting and Exposition (ASH 2007) in Chicago.


    Data presented at ASH includes:

    -- "Long-Term Exposure to the Novel Beta-Blocker Nebivolol as Monotherapy

       or Combination Therapy: Antihypertensive Efficacy and Safety" by

       Vasilios Papademetriou, MD, Professor of Medicine, Georgetown

       University.  [Poster Presentation, P-419: Monday, May 21 from 12 pm to

       1 pm (Riverside Hall)]

       The long-term treatment effects of nebivolol were evaluated in a

       multicenter, 9-month extension study (n=845) of patients who

       successfully completed one of the three randomized, double-blind,

       placebo-controlled registration studies.  Patients received nebivolol

       monotherapy (5 mg, 10 mg, or 20 mg once daily) or nebivolol plus

       adjunct therapy (open-label diuretics or amlodipine).  Outcomes

       demonstrated that nebivolol treatment produced sustained blood pressure

       reductions for the duration of the study period and was well tolerated

       in all treatment groups.  No clinically significant changes in glucose

       or lipids were seen with nebivolol monotherapy during the study.

    -- "Addition of the Beta-Blocker Nebivolol to Ongoing Therapy in the

       Management of Mild-to-Moderate Hypertension" by Alan H. Gradman, MD,

       Chief, Division of Cardiovascular Diseases, The Western Pennsylvania

       Hospital.  [Poster Presentation, P-383: Monday, May 21 from 12 pm

       to 1 pm (Riverside Hall)]

       The blood pressure lowering effects and tolerability of nebivolol added

       to ongoing antihypertensive therapy in patients was evaluated in this

       12-week, randomized, double-blind, placebo-controlled study (n=669).

       Results indicate that, by comparison to placebo, nebivolol

       incrementally lowers blood pressure in mild to moderate hypertensive

       patients when added to ongoing antihypertensive therapy consisting of

       one or two medications from the following classes: ACE inhibitors,

       ARBs, or diuretics, with an incidence of reported adverse events

       similar to placebo.

    -- "Efficacy of the Novel Beta-blocker Nebivolol in Obese and Non-Obese

       Hypertensive Patients" by James R. Sowers, MD, Professor of Medicine

       and Physiology, Director Diabetes and Cardiovascular Center, University

       of Missouri. [Poster Presentation, P-442: Monday, May 21 from 12 pm to

       1 pm (Riverside Hall)]

       The blood pressure lowering effects of nebivolol was compared in non-

       obese and obese hypertensive patients, a population that typically has

       a poorer response to treatment and an increased need for multiple

       medications.   The pooled analysis of three randomized, double-blind,

       placebo-controlled trials of similar design was stratified by patient

       obesity status (BMI greater than or equal to 30 kg/m2) at baseline

       (obese, n=878; non-obese, n=1136).  Results suggest that once-

       nebivolol effectively lowers blood pressure to a similar extent in both

       obese and non-obese hypertensive patients.

"These study results are promising and add to the growing body of data that support nebivolol as a useful treatment for hypertension across a broad population of patients," says Neil Shusterman, MD, Senior Vice President, Clinical Development, Forest Research Institute. "We feel that nebivolol will offer patients and physicians a unique option for managing high blood pressure."

About Nebivolol

Nebivolol is a selective beta 1-adrenergic (cardioselective) receptor antagonist with vasodilating properties and is already approved and successfully marketed for the treatment of hypertension in more than 50 countries outside of North America.

About Forest Laboratories and Its Products

Forest Laboratories is a US-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil-hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

    * Benicar is a registered trademark of Daiichi Sankyo, Inc., and C

      is a registered trademark of Merck Sante s.a.s., subsidiary of Merck

      KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2006 and on Form 10-Q for the periods ended June 30, 2006, September 30, 2006 and December 31, 2006.

CONTACT: Charles E. Triano, Vice President, Investor Relations, of ForestLaboratories, Inc., +1-212-224-6714, ; or On-siteContact: Paddi Hurley of Fleishman-Hillard, +1-917-743-2290,, for Forest Laboratories, Inc.

Web site:

Ticker Symbol: (NYSE:FRX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:11/25/2015)... 2015 Research and Markets ( ) ... - Global Forecast to 2020" report to their ... for 37.21% of the total market share in 2014. ... region is projected to growth at the highest CAGR ... primarily to the fast growing water, industrial gas treatment, ...
(Date:11/24/2015)... , Nov. 24, 2015  Thanks to a donor ... St. Mary,s Medical Center,s Sister Diane Grassilli Center for ... capabilities in San Francisco . ... friend, stepped forward with a gift of $617,320 that ... Digital Mammography with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, ...
(Date:11/24/2015)... Nueva York , 24 de noviembre de ... del Avery Breathing Pacemaker System, se complace anunciar ... Ph.D. como consultor clínico. ... Foto -   ... Jonzon es un fisiólogo y consultor en neonatología ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 24, 2015 , ... Abington Hospital – Jefferson Health is ... Bariatric Surgery Facility for treating individuals living with morbid or extreme obesity. , ... to its members to help them make informed decisions about their healthcare needs. ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Rodney E. Willey , has answered ... venture, Koala Center for Sleep Disorders, provides treatment for snoring and sleep apnea ... opened a Koala Center for Sleep Disorders in the US, one of four in the ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty Health ... have announced their endorsement of the Medical Fitness Network (MFN), a national ... to have the MFN as one of our endorsed organizations,” said ASH Fitness ...
(Date:11/24/2015)... ... , ... Autism Speaks, the world’s leading autism science and advocacy organization, will ... generosity of people around the world. On December 1, supporters can make an online ... share the personal stories behind those gifts. , Just as Black Friday and ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... engineer of patented products, announces Innovative Blending, a household invention that revolutionizes the ... "The Juice & Smoothie Bars market is worth $2 billion," says Scott Cooper, ...
Breaking Medicine News(10 mins):